Loading clinical trials...

Role of Amlodipine in Reduction of CIN | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Role of Amlodipine in Reduction of CIN

The Effect of Low Dose Oral Amlodipine in Renal Protection From Contrast Induced Nephropathy in Diabetic Patients in Intensive Care Unit

NCT07291375•Minia University

View on ClinicalTrials.gov

Summary

The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3

Exclusion Criteria

•patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients

Key Dates

Start Date

December 20, 2025

Primary Completion Date

June 1, 2026

Completion Date

July 1, 2026

Last Updated

December 18, 2025

Enrollment

ESTIMATED participants

Conditions

Contrast-induced Nephropathy

Interventions

Calcium channel blocker

DRUG

Hydration

OTHER

Contacts

Andrew Shehata, Master

CONTACT

0201067820073 andrewlengouini.95@gmail.com

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

NCT06429345

Contrast-induced Nephropathy

View study

ACTIVE_NOT_RECRUITING

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847

Acute Kidney InjuryContrast-induced Nephropathy

View study

ACTIVE_NOT_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Role of Amlodipine in Reduction of CIN

Inclusion Criteria

Exclusion Criteria

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

Clinical Validation of the RENISCHEM L-FABP POC Assay

Contrast Nephropathy Associated FFA

Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans

Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients

Contrast-associated Acute Kidney Injury in Patients With Different Types of Coronary Artery Disease